These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 36588414)

  • 21. Genetically modified live attenuated parasites as vaccines for leishmaniasis.
    Selvapandiyan A; Duncan R; Debrabant A; Lee N; Sreenivas G; Salotra P; Nakhasi HL
    Indian J Med Res; 2006 Mar; 123(3):455-66. PubMed ID: 16778323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination in Leishmaniasis: A Review Article.
    Abdellahi L; Iraji F; Mahmoudabadi A; Hejazi SH
    Iran Biomed J; 2022 Jan; 26(1):1-35. PubMed ID: 34952558
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Lajevardi MS; Gholami E; Taheri T; Sarvnaz H; Habibzadeh S; Seyed N; Mortazavi Y; Rafati S
    Front Immunol; 2022; 13():895234. PubMed ID: 35757692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.
    Gannavaram S; Dey R; Avishek K; Selvapandiyan A; Salotra P; Nakhasi HL
    Front Immunol; 2014; 5():241. PubMed ID: 24904589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of pro-inflammatory cytokine IL-17 in Leishmania pathogenesis and in protective immunity by Leishmania vaccines.
    Banerjee A; Bhattacharya P; Joshi AB; Ismail N; Dey R; Nakhasi HL
    Cell Immunol; 2016 Nov; 309():37-41. PubMed ID: 27444130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Live attenuated Leishmania major p27 gene knockout as a novel vaccine candidate: A study on safety, protective immunity and efficacy against canine leishmaniasis caused by Leishmania infantum.
    Elikaee S; Zarei Z; Khamesipour A; Akhoundi B; Borjian AR; Afshar MJA; Allely QK; Heidari S; Mohebali M
    Acta Trop; 2022 Jan; 225():106153. PubMed ID: 34634264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation.
    Carrión J; Folgueira C; Soto M; Fresno M; Requena JM
    Parasit Vectors; 2011 Jul; 4():150. PubMed ID: 21794145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.
    Ramirez L; Corvo L; Duarte MC; Chávez-Fumagalli MA; Valadares DG; Santos DM; de Oliveira CI; Escutia MR; Alonso C; Bonay P; Tavares CA; Coelho EA; Soto M
    Parasit Vectors; 2014 Jan; 7():3. PubMed ID: 24382098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.
    Shahbazi M; Zahedifard F; Taheri T; Taslimi Y; Jamshidi S; Shirian S; Mahdavi N; Hassankhani M; Daneshbod Y; Zarkesh-Esfahani SH; Papadopoulou B; Rafati S
    PLoS One; 2015; 10(7):e0132794. PubMed ID: 26197085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis.
    Karmakar S; Ismail N; Oliveira F; Oristian J; Zhang WW; Kaviraj S; Singh KP; Mondal A; Das S; Pandey K; Bhattacharya P; Volpedo G; Gannavaram S; Satoskar M; Satoskar S; Sastry RM; Oljuskin T; Sepahpour T; Meneses C; Hamano S; Das P; Matlashewski G; Singh S; Kamhawi S; Dey R; Valenzuela JG; Satoskar A; Nakhasi HL
    Commun Biol; 2021 Jul; 4(1):929. PubMed ID: 34330999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
    Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
    Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Silico Design of Recombinant Chimera T Cell Peptide Epitope Vaccines for Visceral Leishmaniasis.
    Machado AS; Martins VT; Humbert MV; Christodoulides M; Coelho EAF
    Methods Mol Biol; 2022; 2410():463-480. PubMed ID: 34914063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering a vector-based pan-Leishmania vaccine for humans: proof of principle.
    Cecílio P; Oristian J; Meneses C; Serafim TD; Valenzuela JG; Cordeiro da Silva A; Oliveira F
    Sci Rep; 2020 Oct; 10(1):18653. PubMed ID: 33122717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
    Thakur A; Kaur H; Kaur S
    Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigenicity of
    Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
    Front Immunol; 2018; 9():843. PubMed ID: 29740446
    [No Abstract]   [Full Text] [Related]  

  • 40. Live Attenuated
    Banerjee A; Bhattacharya P; Dagur PK; Karmakar S; Ismail N; Joshi AB; Akue AD; KuKuruga M; McCoy JP; Dey R; Nakhasi HL
    J Immunol; 2018 Jan; 200(1):163-176. PubMed ID: 29187586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.